一、2025年度主要财务数据和指标 证券代码：688079 证券简称：美迪凯 公告编号：2026-006 杭州美迪凯光电科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年 度的定期报告为准，提请投资者注意投资风险。 单位：万元 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.上述财务数据及指标为未经审计的合并报表数据，最终数据以公司2025年年度报告中披露数据为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况以及财务状况 公司2025年度实现营业收入66,438.70万元，较上年同期增加17,887.58万元，同比增长36.84%；实现归 属于母公司所有者的净利润-15,501.45万元，较上年同期亏损扩大5,316.87万元；实现归属于母公司所有 者的扣除非经常性损益的净利润-15,786.65万元，较上年同期亏损扩大6,477.93万元。 报告期末公司总资产337 ...

Group 1: Transaction Overview - The company plans to introduce strategic investor Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership) through its subsidiary Zhejiang Meidikai Optical Semiconductor Co., Ltd. [2] - The board of directors approved the proposal for capital increase and share expansion on December 10, 2025, and the relevant agreements have been signed [3]. Group 2: Transaction Progress - As of the announcement date, the company and related parties have signed the capital increase agreement and shareholder agreement, with a total cash capital increase of RMB 200 million received [3]. - Following the capital increase, the registered capital of the optical semiconductor company will increase from RMB 1,008,888,889 to RMB 1,101,447,503, and the company's shareholding will change to 82.44% [3]. Group 3: Performance Forecast - For the fiscal year 2025, the company expects to achieve approximately RMB 664.26 million in revenue, a year-on-year increase of 36.82% [8]. - The company anticipates a net loss attributable to shareholders of approximately RMB -154.41 million, a decrease of RMB 52.57 million compared to the previous year [8]. - EBITDA is projected to be around RMB 65.29 million, reflecting a year-on-year increase of 19.62% [8]. Group 4: Revenue Growth Factors - The revenue increase is attributed to higher sales in semiconductor packaging and testing, as well as new product launches contributing to additional revenue [14]. - Specific revenue contributions include an increase of approximately RMB 94.32 million from semiconductor packaging and testing and RMB 88.90 million from semiconductor acousto-optics [14]. Group 5: Cost and Expense Increases - The company has incurred higher costs due to stock incentive plans, increased interest expenses from larger borrowings, and rising depreciation costs from fixed asset investments [15][16]. - Research and development expenses have also increased, reflecting the company's commitment to new technologies and products [16].

Core Viewpoint - Medike (688079.SH) expects a significant increase in revenue for 2025, while net profit is projected to decline, indicating a mixed financial outlook for the company [1] Financial Projections - The company anticipates achieving an operating revenue of approximately 664.257 million yuan in 2025, representing an increase of about 178.746 million yuan or 36.82% year-on-year [1] - The projected net profit attributable to the parent company is expected to be around -154.414 million yuan, a decrease of approximately 52.568 million yuan compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is estimated to be around -156.947 million yuan, reflecting a decline of about 63.860 million yuan year-on-year [1] Revenue Drivers - The increase in revenue is primarily driven by a rise in semiconductor packaging and testing sales, which are expected to increase by approximately 94.322 million yuan [1] - Sales from semiconductor acousto-optic products are projected to rise by about 88.898 million yuan [1] - The company will begin mass production and delivery of semiconductor process bonding prisms in November 2025, contributing an additional revenue of around 10.969 million yuan [1] - Small-scale production of MEMS devices (MicroLED, uncooled infrared) is expected to generate an increase in sales revenue of approximately 4.256 million yuan [1]

Core Viewpoint - The company Medike (688079) has approved a capital increase for its subsidiary, Zhejiang Medike Optical Semiconductor Co., Ltd., by introducing a strategic investor, Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership), with an investment of 200 million yuan at a pre-investment valuation of 2.18 billion yuan [1] Group 1: Capital Increase Details - The strategic investor will hold an 8.40% stake in Medike Optical Semiconductor after the capital increase [1] - The funds from this capital increase will primarily be used for the main business of Medike Optical Semiconductor and other purposes agreed upon by the investor [1] - The capital raised cannot be transferred to Medike or its affiliates for any purpose [1] Group 2: Financial Performance - In 2024, Medike Optical Semiconductor is projected to have a revenue of 313 million yuan and a net loss of 42.47 million yuan [2] - For the first three quarters of 2025, the company reported a revenue of 264 million yuan and a net loss of 65.77 million yuan [2] Group 3: Strategic Implications - The capital increase is expected to enhance the financial strength of Medike Optical Semiconductor, meeting the capital needs for its business development and creating synergistic effects [2] - The capital increase agreement includes provisions for potential share buybacks, allowing Medike to repurchase shares from the investor within four years under certain conditions [2] - Medike remains the controlling shareholder of Medike Optical Semiconductor post-capital increase, and the subsidiary will continue to be included in Medike's consolidated financial statements [3] Group 4: Business Strategy - Medike focuses on product differentiation and is actively improving its business and product structure, investing in semiconductor optoelectronics, micro-nano circuits (mainly MEMS), semiconductor packaging and testing, precision optics, micro-nano optics, and smart terminal manufacturing [3] - The company is increasing the proportion of its products in semiconductor optoelectronics, micro-nano circuits, and semiconductor packaging and testing, optimizing its customer structure and enhancing the semiconductor device industry chain [3]

Group 1 - The second largest shareholder of Medike (688079), Hong Kong Fengsheng Jiamei (International) Investment Co., Ltd., has announced a plan to reduce its stake by up to 3% [1][3] - The planned reduction corresponds to a market value of approximately 148 million yuan based on the closing price prior to the announcement [3][4] - Medike's stock price has seen a significant increase of 55.39% from April 9 to August 18, while the overall market rose by 18.52% during the same period [3][4] Group 2 - Since its listing in 2021, Medike has faced declining annual net profits, with a notable loss in 2023 [1][5] - The company reported a net profit of approximately -159.92 million yuan in the first quarter of 2025, although this represented a reduction in losses compared to the previous year [5][6] - Medike is actively pursuing asset acquisitions to bolster its position, having completed the acquisition of 100% stakes in Haishuo Li Optoelectronics Technology (Suzhou) Co., Ltd. and INNOWAVE VIETNAM CO., LTD. [6]

Investment Rating - The report assigns a "Buy" rating to the company, expecting the stock price to outperform the industry index by over 15% in the next six months [4][19]. Core Views - The company is acquiring 100% equity of KEM TECH CORP's subsidiary, Haisholi Optoelectronics Technology (Suzhou) Co., Ltd., for 2 billion KRW, and 100% equity of INNOWAVE VIETNAM CO., LTD. for 1 billion KRW, enhancing its overseas presence and entering the Samsung supply chain [1][2]. - The acquisitions are expected to strengthen the company's position in the optical electronics and semiconductor sectors, particularly in the Korean market, which is a strategic focus for overseas expansion [2]. - The company reported a revenue of 1.49 billion CNY in Q1 2025, a year-on-year increase of 29.02%, with a reduction in net losses, indicating improved profitability [3]. Financial Summary - Revenue projections show a growth trajectory from 321 million CNY in 2023 to 1,298 million CNY in 2027, with a compound annual growth rate (CAGR) of approximately 51.4% in 2024 [1][11]. - The net profit is expected to turn positive by 2026, with estimates of -81 million CNY in 2025, 153 million CNY in 2026, and 225 million CNY in 2027 [1][9]. - The company's return on equity (ROE) is projected to improve from -7.6% in 2024 to 13.5% in 2027, reflecting a recovery in profitability [1][11]. Market Position and Product Development - The company is focusing on semiconductor optoelectronics, MEMS, and precision optics, with products being developed for various applications including communication, consumer electronics, and smart vehicles [9]. - The report highlights the increasing penetration of periscope lenses in high-end smartphones, projecting the market size for periscope cameras in China to reach 287.2 billion CNY by 2025 [8]. - The company has developed several optical components and solutions, including diffraction optical elements and optical micro-lens arrays, which are expected to enhance its competitive edge in the market [8].

Core Viewpoint - The company is preparing for its 2024 annual shareholders' meeting, where various proposals will be discussed, including the appointment of auditors, financial reports, and capital changes. Group 1: Meeting Procedures - Shareholders and their representatives must arrive 30 minutes before the meeting to complete registration and present necessary identification documents [2][3] - The meeting will follow a specific agenda, allowing shareholders to exercise their rights to speak, inquire, and vote [2][3][4] - Voting will be conducted both on-site and online, with specific time frames for each method [5] Group 2: Financial Reports and Proposals - The company will present its 2024 annual financial report, which indicates a projected revenue increase of 51.38% despite a net loss for the year [8][9] - The profit distribution plan for 2024 proposes no cash dividends or stock bonuses due to the company's current financial situation and investment needs [8][11] - The company plans to continue its strategic investments in technology and capacity expansion, anticipating improved performance in the coming years [9][10] Group 3: Auditor Appointment - The company proposes to reappoint Tianjian Accounting Firm as its auditor for the 2025 fiscal year, with an audit fee of 750,000 RMB [11][12] - Tianjian has a strong track record and familiarity with the company's operations, which supports the decision for reappointment [11][12] Group 4: Capital and Financing - The company intends to apply for a credit limit of up to 1.5 billion RMB from financial institutions to support its operational and investment needs [19] - The company will provide guarantees for its subsidiaries' loans within the approved credit limit [19] - A proposal for foreign exchange hedging activities is also on the agenda, aimed at mitigating currency risk associated with international transactions [21][22] Group 5: Governance Changes - The company plans to amend its articles of association to eliminate the supervisory board, transferring its responsibilities to the audit committee of the board [30] - This change is part of a broader effort to enhance corporate governance and streamline operations [30]